Exosome and extracellular-vesicle (EV) topicals are everywhere now: post-procedure serums, recovery gels, scalp treatments, "regenerative" facials. Practices selling them usually ask the wrong question first — is this ingredient allowed? — when the question that actually determines regulatory risk is what are we claiming it does?
FDA classifies products by intended use, and it reads intended use directly from your marketing. The same jar of serum can be a lawful cosmetic on one web page and an unapproved drug on another, with no change to what's inside it.
A topical is marketed as a cosmetic when its claims stay limited to appearance — how skin looks and feels:
The same product becomes a drug — and, being exosome-derived, potentially a biologic — when the marketing claims it acts on the body:
Between those two lists sits a middle category that catches many practices by surprise: structure/function claims. "Stimulates collagen production," "reduces inflammation," "boosts cellular renewal" describe an effect on the structure or function of the body, not on appearance. They are drug claims under the intended-use test even when the product is sold as a cosmetic and the language sounds routine in beauty marketing.
FDA has issued a public safety notification on exosome products, and its position has been consistent: there are no FDA-approved exosome products for treating diseases or medical conditions, and exosome products marketed to diagnose, treat, cure, or prevent disease are regulated as drugs and biological products requiring FDA review.
That notification addresses therapeutic and regenerative uses — injections, IV infusions, treatments for orthopedic or pulmonary conditions — rather than cosmetics. It does not say a topical containing vesicles is per se unlawful. It does mean that the moment your topical marketing reaches for treatment language, you have moved into the category FDA is actively policing.
1. Application through a disrupted skin barrier. This is the one most often missed. A serum applied to intact skin is surface cosmetic use. The same serum applied immediately after microneedling, fractional laser, or RF microneedling — while channels are open — is delivery into living tissue. That is administration of a biologic, not cosmetic application, and no device is FDA-cleared for combined biologic delivery. Marketing copy tends to confirm it in writing: "so it can absorb deeper," "delivered directly into the skin," "penetrates where creams can't."
If your practice offers exosomes as a post-procedure add-on, that service should be reviewed by healthcare counsel before it is promoted — this is not a copy-editing problem.
2. Vesicle source and product identity. "Exosome" is used loosely in the market. Plant-derived vesicles, biomimetic or "exosome-like" vesicles, conditioned media, and human-cell-derived exosomes are materially different products with different regulatory profiles, and human-cell-derived material carries considerably more scrutiny. Practices frequently cannot say which one they are selling. Know your source, keep the documentation, and check the specific product and manufacturer against FDA warning letters and import alerts before you promote it.
It is also worth being candid internally about the evidence: research on vesicles in skin is genuinely developing, and the stronger findings involve professional use where the barrier has been disrupted. Evidence that intact skin absorbs biologically meaningful quantities is more limited — which is another reason appearance-only claims are the defensible ones.
Blanket advice to "avoid exosomes entirely" costs practices a legitimate product category. Blanket comfort — "it's just a serum" — walks them into an FDA letter. The accurate position is narrower and more useful than either: the ingredient is not the violation; the claim is. A cosmetic exosome topical marketed on appearance is defensible. The same product marketed on regeneration, or applied through open microchannels, is not.
Related reading: Stem Cells, Exosomes, and the Claims That Draw FDA Warning Letters.
This article is educational content about publicly available regulatory guidance. It is not legal advice; consult healthcare counsel for guidance specific to your practice.
Enter your email to unlock the printable version — yours to keep and share with your team.
We may send occasional compliance updates. Unsubscribe anytime.
Run a free AI compliance scan — your score and sample findings in about a minute.
Analyze My Website — Free